- Email: [email protected]
Psoralen inactivated double-stranded RNA viral vaccines
Patent Report Modified live Sendai virus vaccine diluted by passage through incubated culture medium for providing a cold strain
Simonsen-Lab. US 4554 158; 19 November 1985 A vaccine for immunization against Sendal disease comprises live Sendal viruses modified and diluted by passages through incubated culture medium for providing a cold strain of live modified Sendai virus fluid. The incubated culture medium is maintained at 25-35°C for 48-96 h. The vaccine can be administered through an aerosol so that large numbers of animals can be immunized quickly and easily. 052-86 Vaccinia virus containing DNA coding for rabies glycoprotein useful as vaccine and for the production of the glycoprotein and antisera
Transgene World 8504 810; 7 November 1985 A vaccinia virus containing all or part of the D N A sequence coding for an antigenic glycoprotein of rabies is claimed. The virus is used to infect mammalian cells and anti-rabies vaccines containing this virus or the glycoprotein are obtained by cultivating the infected cells. 053-86 Cell line for the continuous production of human T-lymphotropic retro viruses HTLV-III for the production of AIDS vaccines and antibody detection
US Dept. Commerce World 8504 897; 7 November 1985 A cell system for the reproducible detection and isolation of human T-lymphotropic retro viruses (HTLV-family) with cell killing effects (HTLV-III) from patients with AIDS, preAIDS and in healthy carriers is claimed. A target T lymphocyte is infected with HTLV-III virus, the normal cytopathic effect of HTLV-III is overcome and the immortal growth capacity of the target T cell is preserved. The resulting T cell line H9/HTLV-IIIB (ATCC CRL 8543) is claimed which has the capacity for immortal growth and is capable of continuous large scale production of HTLV-III. This virus can be used for the production of AIDS vaccines and for virus antibody detection in blood samples. 054-86 Lyophilized vaccine containing recombinant hepatitis B virus surface antigen adsorbed onto aluminum gel in the presence of stabilizer
about 106 to 10'j p.f.u, ml i wherein said inactivation is as a result of irradiation of BTV in the presence of an inactivating furocoumarin with long wavelength ultraviolet light at a temperature below about 40°C for a time sufficient to inactivate said BTV to a non-infectious degree and an immunologic adjuvant. 056-86 Hepatitis B core antigen vaccine
Dept. Health & Human Services US 4547 367; 15 October 1985 A method of protecting chimpanzees by administering a vaccine prepared by a process which comprises centrifuging and isolating HBcAg from the liver of an infected chimpanzee, mixing said HBcAg with a suitable adjuvant to form a vaccine and injecting said vaccine into the chimpanzee. 057-86 Hepatitis B core antigen vaccine made by recombinant DNA
Dept. Health & Human Services US 4547 368; 15 October 1985 A method of protecting chimpanzees by administering a vaccine prepared by a process which comprises centrifuging and isolating HBcAg from the supernatant fluid of cloned cells containing recombinant hepatitis B virus DNA, mixing said HBcAg with a suitable adjuvant to form a vaccine and injecting said vaccine into a chimpanzee. (t58-86 Cattle (respiratory system) RS virus strain having reduced toxicity suitable for use as vaccine
Biseibutsu Japan 0196 187; 4 October 1985 A cattle RS virus strain having reduced toxicity is described and obtained by subcultivation of a cattle RS virus isolated from cattle RS virus spontaneous infected cattle by culturing cells at a lower temperature so reducing toxicity of the virus. This strain is suitable for use as vaccine in the prevention of respiratory system diseases in cattle. The virus may be inoculated into the abdominal cavity, subcutaneous tissue, muscle or nasal cavity of mice, guinea pigs and young cattle without any abnormal effects being observed. When a virus with strong toxicity is injected into cattle previously immunized with the present strain no abnormal symptoms are observed. 059-86
Chemo-Sero-Ther. Res. Inst. Eur. 156 242; 2 October 1985 A process is described for the production of a lyophilized hepatitis B virus (HBV) vaccine containing pure HBV antigen adsorbed on aluminum gel in the presence of a stabilizer. The HBV surface antigen is produced by recombinant D N A techniques in which an HBV surface antigen is introduced into a vector, e.g. pMA56 or pAH203, containing a suitable promoter for expression of this gene, and the recombinant vector is used to transform a suitable host, e.g: Escherichia coli, yeast, animal cell cultures etc. The recombinant antigen is mixed with an aluminium hydroxide or phosphate gel and amino acid (or salt) and/or sugar, optionally together with a colloid to form the vaccine. The vaccine is stable during longterm storage and can be dissolved in water for administration. 055-86 Psoralen inactivated double-stranded RNA viral vaccines
Adv. Genetics Res. Inst. US 4545 987; 24 December 1985 A vaccine useful for inoculation of a mammalian host susceptible to infection by Bluetongue virus (BTV), which comprises at least one furocoumarin-inactivated BTV serotype in from 134
Vaccine, Vol. 4, June 1986
Process for producing a hepatitis B infection preventing vaccine
Green Cross Corporation US 4565 697; 7 January 1986 A process for producing a hepatitis B infection preventing vaccine containing, as main component thereof, hepatitis B surface antigen (HBsAg) and free of hepatitis B infectivity and of human plasma components. 060-86 Vaccine compositions
Lee BioMolecular Research Labs. US 4568 542; 7 January 1986 An immunologically reactive vaccine composition comprising a physiologically acceptable medium for vaccine use and effective amounts of inactivated, non-infective virus-containing normal cells or tumor cells having cell-associated antigens capable of eliciting an immunological response and having had D N A or R N A contained therein covalently bonded to psoralen or a psoralen derivative in the presence of long wavelength ultraviolet light. 061-86
Simonsen-Lab. US 4554 158; 19 November 1985 A vaccine for immunization against Sendal disease comprises live Sendal viruses modified and diluted by passages through incubated culture medium for providing a cold strain of live modified Sendai virus fluid. The incubated culture medium is maintained at 25-35°C for 48-96 h. The vaccine can be administered through an aerosol so that large numbers of animals can be immunized quickly and easily. 052-86 Vaccinia virus containing DNA coding for rabies glycoprotein useful as vaccine and for the production of the glycoprotein and antisera
Transgene World 8504 810; 7 November 1985 A vaccinia virus containing all or part of the D N A sequence coding for an antigenic glycoprotein of rabies is claimed. The virus is used to infect mammalian cells and anti-rabies vaccines containing this virus or the glycoprotein are obtained by cultivating the infected cells. 053-86 Cell line for the continuous production of human T-lymphotropic retro viruses HTLV-III for the production of AIDS vaccines and antibody detection
US Dept. Commerce World 8504 897; 7 November 1985 A cell system for the reproducible detection and isolation of human T-lymphotropic retro viruses (HTLV-family) with cell killing effects (HTLV-III) from patients with AIDS, preAIDS and in healthy carriers is claimed. A target T lymphocyte is infected with HTLV-III virus, the normal cytopathic effect of HTLV-III is overcome and the immortal growth capacity of the target T cell is preserved. The resulting T cell line H9/HTLV-IIIB (ATCC CRL 8543) is claimed which has the capacity for immortal growth and is capable of continuous large scale production of HTLV-III. This virus can be used for the production of AIDS vaccines and for virus antibody detection in blood samples. 054-86 Lyophilized vaccine containing recombinant hepatitis B virus surface antigen adsorbed onto aluminum gel in the presence of stabilizer
about 106 to 10'j p.f.u, ml i wherein said inactivation is as a result of irradiation of BTV in the presence of an inactivating furocoumarin with long wavelength ultraviolet light at a temperature below about 40°C for a time sufficient to inactivate said BTV to a non-infectious degree and an immunologic adjuvant. 056-86 Hepatitis B core antigen vaccine
Dept. Health & Human Services US 4547 367; 15 October 1985 A method of protecting chimpanzees by administering a vaccine prepared by a process which comprises centrifuging and isolating HBcAg from the liver of an infected chimpanzee, mixing said HBcAg with a suitable adjuvant to form a vaccine and injecting said vaccine into the chimpanzee. 057-86 Hepatitis B core antigen vaccine made by recombinant DNA
Dept. Health & Human Services US 4547 368; 15 October 1985 A method of protecting chimpanzees by administering a vaccine prepared by a process which comprises centrifuging and isolating HBcAg from the supernatant fluid of cloned cells containing recombinant hepatitis B virus DNA, mixing said HBcAg with a suitable adjuvant to form a vaccine and injecting said vaccine into a chimpanzee. (t58-86 Cattle (respiratory system) RS virus strain having reduced toxicity suitable for use as vaccine
Biseibutsu Japan 0196 187; 4 October 1985 A cattle RS virus strain having reduced toxicity is described and obtained by subcultivation of a cattle RS virus isolated from cattle RS virus spontaneous infected cattle by culturing cells at a lower temperature so reducing toxicity of the virus. This strain is suitable for use as vaccine in the prevention of respiratory system diseases in cattle. The virus may be inoculated into the abdominal cavity, subcutaneous tissue, muscle or nasal cavity of mice, guinea pigs and young cattle without any abnormal effects being observed. When a virus with strong toxicity is injected into cattle previously immunized with the present strain no abnormal symptoms are observed. 059-86
Chemo-Sero-Ther. Res. Inst. Eur. 156 242; 2 October 1985 A process is described for the production of a lyophilized hepatitis B virus (HBV) vaccine containing pure HBV antigen adsorbed on aluminum gel in the presence of a stabilizer. The HBV surface antigen is produced by recombinant D N A techniques in which an HBV surface antigen is introduced into a vector, e.g. pMA56 or pAH203, containing a suitable promoter for expression of this gene, and the recombinant vector is used to transform a suitable host, e.g: Escherichia coli, yeast, animal cell cultures etc. The recombinant antigen is mixed with an aluminium hydroxide or phosphate gel and amino acid (or salt) and/or sugar, optionally together with a colloid to form the vaccine. The vaccine is stable during longterm storage and can be dissolved in water for administration. 055-86 Psoralen inactivated double-stranded RNA viral vaccines
Adv. Genetics Res. Inst. US 4545 987; 24 December 1985 A vaccine useful for inoculation of a mammalian host susceptible to infection by Bluetongue virus (BTV), which comprises at least one furocoumarin-inactivated BTV serotype in from 134
Vaccine, Vol. 4, June 1986
Process for producing a hepatitis B infection preventing vaccine
Green Cross Corporation US 4565 697; 7 January 1986 A process for producing a hepatitis B infection preventing vaccine containing, as main component thereof, hepatitis B surface antigen (HBsAg) and free of hepatitis B infectivity and of human plasma components. 060-86 Vaccine compositions
Lee BioMolecular Research Labs. US 4568 542; 7 January 1986 An immunologically reactive vaccine composition comprising a physiologically acceptable medium for vaccine use and effective amounts of inactivated, non-infective virus-containing normal cells or tumor cells having cell-associated antigens capable of eliciting an immunological response and having had D N A or R N A contained therein covalently bonded to psoralen or a psoralen derivative in the presence of long wavelength ultraviolet light. 061-86